Ohm wrote, Then only allowing two doses in four

Ohm wrote,

Quote:

---

Then only allowing two doses in four weeks that screwed up our trial. That damn sure is the FDA's fault

---

Forgive the recap. Most of you here remember (but perhaps not everyone: thus this note) exactly what Ohm is referring here.

In the CD12 trial of Leronlimab vs. Covid, FDA allowed only two weekly doses instead of the four Cytodyn wanted, and then compounded that mistake by insisting that the trial length be 28 days instead of the 14 Cytodyn wanted.

Leron's survival rate against Covid at 14 days, after the two weekly doses, was 82% higher than the placebo arm's. Two weeks later, after two weeks of no (fricking) treatment, the survival rate had reverted to something similar to the placebo arm's.

In other words, Leron could probably have allowed us to avert four out of every five Covid deaths. The results were right there, but without statistical significance re the primary endpoint, the FDA chose to say, out loud, and in public, that Leronlimab had demonstrated no efficacy in any trial. Murder most foul.

Sorry. I have to say that every once in a while. Will never get over it.